Table 2.
Biological, virological, and pathological characteristics of the 46 PML-IRIS patients.
| Value | N | |
|---|---|---|
| Median HIV viral load (VL) before combined antiretroviral therapy (cART) (/ml) (range) | 100,000 [29–1,000,000] | 31 |
| Unmasking PML-immune reconstitution inflammatory syndromes (PML-IRIS) | 100,000 [40–750,000] | 13 |
| Paradoxical PML-IRIS | 125,000 [29–1,000,000] | 18 |
| Median HIV VL at IRIS onset (/ml) (range) | 490 [10–100,000] | 30 |
| Unmasking PML-IRIS | 100 [40–100,000] | 14 |
| Paradoxical PML-IRIS | 710 [10–10,000] | 16 |
| Median CD4 T cell count before cART (/μl) (range) | 45 [0–301] | 37 |
| Unmasking PML-IRIS | 48 [8–301] | 18 |
| Paradoxical PML-IRIS | 43 [0–284] | 19 |
| Median CD4 T cell count at IRIS onset (/μl) (range) | 101 [20–610] | 28 |
| Unmasking PML-IRIS | 101 [49–464] | 10 |
| Paradoxical PML-IRIS | 101 [20–610] | 18 |
| Positive PCR for JCV in cerebrospinal fluid (%) | 32 (84%) | 38 |
| Unmasking PML-IRIS | 17 (94%) | 18 |
| Paradoxical PML-IRIS | 15 (75%) | 20 |
| Detection of John Cunningham virus in brain biopsy (%) | 19 (90%) | 21 |
| Pathologically proven PML (%) | 10 (48%) | 21 |
| Pathologically proven PML-IRIS (%) | 20 (95%) | 21 |
N, number of data available for characteristic.